Skip to main content
  • 138 Accesses

Abstract

Sarcoidosis is a multisystemic granulomatous disease of unknown etiology. The available evidence suggests that the disease results from an exposure of genetically susceptible hosts to specific environmental agents, which trigger a Th1 immunological response in the involved organs, leading to granuloma formation. Sarcoidosis usually presents with bilateral hilar lymphadenopathy, and pulmonary, cutaneous and ocular involvement, although any organ can be affected. The diagnosis is based on a compatible clinical and radiological picture, demonstration of noncaseating granulomas with negative cultures for mycobacteria and fungus, and exclusion of other granulomatous diseases. In general, an acute onset, particularly Löfgren’s syndrome, has a good prognosis, whereas an insidious presentation heralds a chronic disease. Corticosteroids should be administered when severe and progressive disease involves major organs such as lungs, eyes, heart and central nervous system. Several drugs may be useful as alternative therapies in cases refractory to corticosteroid treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG Statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149–73/Am J Respir Crit Care Med 1999; 160: 736–55.

    Google Scholar 

  2. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111–8.

    Article  CAS  PubMed  Google Scholar 

  3. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis. Environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170: 1324–30.

    Article  PubMed  Google Scholar 

  4. Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, et al. Job and industry classifications associated with sarcoidosis in a case-control etiologic study of sarcoidosis (ACCESS). J Occup Environ Med 2005; 47: 226–34.

    Article  PubMed  Google Scholar 

  5. Spagnolo P, du Bois RM. Genetics of sarcoidosis. Clin Dermatol 2007; 25: 242–9.

    Article  PubMed  Google Scholar 

  6. Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003; 253: 18–30.

    Article  CAS  PubMed  Google Scholar 

  7. Mañá J, Gómez-Vaquero C, Montero A, Salazar A, Marcoval J, Valverde J, et al. Löfgren's syndrome revisited: A study of 186 patients. Am J Med 1999; 107: 240–5.

    Article  PubMed  Google Scholar 

  8. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr, and the ACCESS Research Group.Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75–86.

    CAS  PubMed  Google Scholar 

  9. Lynch JP, White ES. Pulmonary sarcoidosis. Eur Respir Mon 2005; 32: 105–29.

    Google Scholar 

  10. Mañá J, Marcoval J, Graells J, Salazar A, Peyrí J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133: 882–8.

    Article  PubMed  Google Scholar 

  11. Hoitma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: A clinical dilemma. Lancet Neurol 2004; 3: 397–407.

    Article  Google Scholar 

  12. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Weschsler B, Huong DLT, et al. Cardiac sarcoidosis. A retrospective study of 41 cases. Medicine 2004; 83: 315–34.

    Article  PubMed  Google Scholar 

  13. Mañá J, Montero A, Vidal M, Marcoval J, Pujol R. Recurrent sarcoidosis: A study of 17 cases with 24 episodes of recurrence. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 212–21.

    PubMed  Google Scholar 

  14. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis. A systematic review. JAMA 2002; 287: 1301–7.

    Article  CAS  PubMed  Google Scholar 

  15. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine 1999; 78: 65–111.

    Article  CAS  PubMed  Google Scholar 

  16. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois RM, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795–802.

    Article  CAS  PubMed  Google Scholar 

  17. Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C.Aggressive therapy for neurosarcoidosis. Long-term follow-up of 48 treated patients. Arch Neurol 2007; 64: 691–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mañá, J. (2008). Sarcoidosis. In: Shoenfeld, Y., Cervera, R., Gershwin, M.E. (eds) Diagnostic Criteria in Autoimmune Diseases. Humana Press. https://doi.org/10.1007/978-1-60327-285-8_37

Download citation

Publish with us

Policies and ethics